Rhythm Pharmaceuticals is a company dedicated to changing how rare genetic diseases of obesity are diagnosed and treated. Rare genetic diseases of obesity are distinct from general obesity and are characterized by early-onset, severe obesity, and insatiable hunger, known as hyperphagia. Specifically, Rhythm’s unique focus is on rare genetic diseases of obesity that are caused by genetic deficiencies within the melanocortin-4 receptor (MC4R) pathway. Rhythm is located in Boston, MA. Juliana Simonetti, MD is the Director of Obesity Medicine and Co-director of Comprehensive Weight Management Program at the University of Utah.
Join us for this Breakfast Symposium!
This is a NON-CME event.